Dyne Therapeutics, Inc. (DYN)
| Market Cap | 3.00B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -446.21M |
| Shares Out | 165.22M |
| EPS (ttm) | -3.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,127,326 |
| Open | 18.00 |
| Previous Close | 18.04 |
| Day's Range | 18.00 - 18.93 |
| 52-Week Range | 8.06 - 25.00 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 37.00 (+103.74%) |
| Earnings Date | May 4, 2026 |
About DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price target is $37.0, which is an increase of 103.74% from the latest price.
News
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive...
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care exp...
Dyne Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
The company anticipates a pivotal year in 2026, with commercial launch preparations for DMD and a robust pipeline of eight clinical programs. Positive DMD data, regulatory alignment, and a differentiated platform support confidence in upcoming approvals and market entry.
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enroll...
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-r...
Dyne Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
FORCE platform clinically validated in DMD and DM1, enabling a robust pipeline of eight rare muscle disease programs. Zirasatersen shows strong efficacy and safety, with commercial launch planned for early 2026 and DM1 to follow. Market expansion includes four additional DMD exons, tripling addressable patients.
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 -
Dyne Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive...
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, e...
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEV...
Dyne Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Two late-stage neuromuscular programs showed unprecedented clinical and functional improvements, with regulatory and commercial milestones set for 2026–2027. Platform validation supports pipeline expansion, and operational readiness is in place for upcoming launches.
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive...
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive...
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Transcript: Study Result
The DELIVER trial in DMD met its primary endpoint, showing a robust, statistically significant increase in dystrophin and early, sustained functional improvements across six clinical measures, with a favorable safety profile. These results support a planned BLA submission for accelerated approval in 2026 and validate the FORCE platform for broader neuromuscular indications.
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing late-stage programs in DMD and DM1, with product launches targeted for early 2027 and 2028. Robust clinical data show significant functional and biomarker improvements, supporting U.S. accelerated approval and a strong commercial opportunity.
Dyne Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Key milestones include a pivotal DMD data readout in December, BLA submission in 2026, and a planned launch in 2027. The DM1 program faces a short enrollment delay but remains on track for phase III. Both programs emphasize robust clinical endpoints and global expansion.
Dyne Therapeutics Transcript: Stifel 2025 Healthcare Conference
Management outlined progress on DMD and DM1 programs, with pivotal DMD data expected soon and DM1 enrollment expanding. Launches are targeted for 2027-2028, with robust commercial and manufacturing plans in place. Additional pipeline and FSHD timelines are anticipated for 2026.
Dyne Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Recent industry acquisitions validate the neuromuscular therapeutic space and the company's next-gen approach. DMD data is expected in December, with strong dystrophin and functional results so far. DM1 enrollment faced delays but is progressing, and both programs pursue accelerated approval.